Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19

• Status: Terminated
• Trial end date: 2021-02-02
• Target enrollment: 0
• Participant gender: All

Summary

This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark
• Treatments: Azithromycin; Chloroquine; Chloroquine diphosphate; Hydroxychloroquine

Criteria

Inclusion Criteria:

• Patient admitted to a Danish emergency department, lung medical department or medical department

• Age >18 years

• Hospitalized <48 hours

• Positive COVID-19 test/diagnosis during the hospitalization

• Signs informed consent

Exclusion Criteria:

• If the patient uses > 5 LO2/min at time of recruitment

• Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates

• Pregnancy

• Breastfeeding

• Neurogenic hearing loss

• Psoriasis

• Retinopathy

• Maculopathy

• Changes in vision field

• Severe liver disease other than amoebiases

• Severe gastrointestinal, neurological or haematological disorders

• eGFR < 45 ml/min/1.73m2

• Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval

• Myasthenia Gravis

• Uses Digoxin

• Glucose-6-phosphate dehydrogenase deficiency

• Porphyria

• Hypoglycemia at any time since hospitalization

• Severe mental illness which significantly impedes cooperation

• Severe linguistic problems that significantly impedes cooperation

• Treatment with sickle alkaloids